Navigation Links
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
Date:11/23/2007

AMSTERDAM, November 23 /PRNewswire/ -- Kiadis Pharma announces today that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of Hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR by its principal investigator Dr. Denis Claude Roy, who also presents data on the functionality of Rhitol. In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH.

ATIR: presentation of clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy

Title poster: "Phase I/II clinical trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte Infusions depleted of Alloreactive Cells using ATIR may improve outcome without causing GvHD

- Abstract #2976; Poster 2976, Board #195-III (10 December,5-7 pm)

Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not induce acute GVHD, and suggests a clinical benefit for patients receiving the highest DLI doses to accelerate T cell reconstitution. This PDT strategy represents an appealing alternative for older patients and those at high risk for GVHD"

Rhitol: presentation on functionality of Rhitol in chronic GvHD by Dr. Denis-Claude Roy

Title poster: " anti-Chronic Graft Versus Host Disease activity through a regulatory T Cell dependent mechanism after photodynamic therapy.

- Abstract #3280; Poster 3280; Board #499-III (10 December,5-7 pm)

Dr. Denis-Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "our results demonstrate that TH9402 PDT not only eliminates activated T cells, but preserves Tregs, with the functional ability to inhibit
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
(Date:9/18/2014)... can expect to pay higher employee contributions for their ... resource officers about the impact of the Patient Protection ... Obamacare) conducted by the Darla Moore School of Business ... , Patrick Wright, a professor in strategic human resource ... HR Officers. The survey is distributed to more than ...
(Date:9/18/2014)... to develop tools that would allow them to clearly ... a neuron fires to the resulting behavior in a ... working to develop a range of new tools to ... such tool that provides a new way of mapping ... collaboration between Viviana Gradinaru (BS ,05), assistant professor of ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... much about it. FlameEz.com is launched to provide the latest information ... of the most feared illnesses in middle and old age. ... ... Millions of Americans are affected by chronic inflammation without knowing much ...
... a ,must book-mark site,BETHESDA, Md., Jan. 14 The ... Foundation,s Web site -- www.cff.org -- the ... its "Best of the Web" review of 2008, the ... about cystic fibrosis. , , "This ...
... in French Hospital Market with More Than 130 ... ("Global Med" or the "Company") (OTC Bulletin Board: ... today announced that its subsidiary, Inlog, has licensed ... Serveur" in France) to nineteen additional hospitals during ...
... to Treat Diseases (HTDS) www.htdsmedical.com management ... agreement with Shenzhen Mellow Hope Pharm Industrial Co., ... biggest exporter of Biological Vaccines in China, and ... influenza, tetanus, diphtheria and other diseases; Blood based ...
... Quality Program ReviewsSEATTLE, Jan. 14 MetaStar, ... clinical guidelines and software from Milliman Care ... non-physician medical care reviews throughout the state. ... Milliman Care Guidelines (R) suite, MetaStar now ...
... insulin and oral human growth hormone formulations provide ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ... Cobalamin(TM) oral drug delivery product development programs. The ... B12 oral uptake mechanism to facilitate oral absorption ...
Cached Medicine News:Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 2Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 3Health News:Cystic Fibrosis Foundation Web Site Rated 'Best of the Web' 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 3Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 2Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 3
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
Rad-5 signal extraction pulse oximeter™...
... with Bluetooth® Wireless Technology provides freedom ... and secure transfer of patient data ... The lightweight wrist-worn patient module wirelessly ... display, improving patient mobility and reducing ...
Weighing just two ounces, this durable, self-contained unit delivers an accurate pulse rate and bloodoximetry in just seconds....
Medicine Products: